DSIJ Mindshare

Index trend and stocks in action April 08, 2019
Karan Dsij
/ Categories: Trending, Pre Morning

Index trend and stocks in action April 08, 2019

After opening the session on a positive note, the Nifty turned lackluster and traded in a defined range for the major part of the session. But in the last hour of trading, bulls were seen in a rush and Nifty surged in later part of the session and ended the day at 11,666, up by 0.59 per cent. The price action formed a small body bull candle carrying minor wick on either side. Going ahead, the 8-day moving average, which is placed around 11616, is likely to act as an immediate support, while the major support is placed around 11,559, which is the low of last week. On the upside, 11,760 is likely to act as a resistance level and sustaining above this level decisively would lead to further acceleration of upward momentum.

NIIT Technologies: NIIT Technologies announced that the funds affiliated with Baring Private Equity Asia (BPEA) have signed definitive agreements to purchase approximately 18.85 million shares of NIIT Technologies, approximately 30 per cent shareholding from NIIT and other promoter entities at a price of Rs 1394 per share.

Eris Lifesciences: The company has notified having executed a share purchase agreement with Rajesh Dhuria (one of the founders & promoters of KINEDEX) with the intent to have full ownership and control of the said subsidiary (KINEDEX) and to make KINEDEX a wholly-owned subsidiary through purchase of 32,507 equity shares of face value of Rs. 10 each (equivalent to 17.81 per cent).

Lumax Auto Technologies: The company has sold assets (including plant & machinery, allied infrastructures and capital work-in-progress) of PCB manufacturing for Rs. 22.45 crore. The company has also sold inventory at Rs. 23.94 crore. Both have been sold to Lumax Industries.

Torrent Pharma: The audit at Dahej plant of the company was carried out by USFDA in March 2019. The company has received certain observations which are procedural in nature and the company is confident of addressing them satisfactorily.

Colgate Palmolive (India): The company has clarified that the Maharashtra FDA’s recent action pertains to only one specific variant of toothpaste, Colgate Sensitive, which is known to provide benefit to sensitive teeth. The aforesaid action of Maharashtra FDA only pertains to their view that certain benefits mentioned on the pack cause the product to fall under a drug licence. The quality and benefits of Colgate Sensitive Toothpaste are not at issue.

Tata Steel: India operations achieved the highest ever crude steel production in 4QFY19 driven by better plant availability across the locations including ramp-up at Tata Steel BSL. The 4QFY19 production grew by 46 per cent YoY to 4.47 mn tonnes. India operations recorded the highest ever sales volume in 4QFY19. The volumes increased by 56 per cent YoY and 22 per cent QoQ to 4.73 mn tonnes during the quarter.

Cadila Healthcare: Zydus Cadila has received the tentative approval from the USFDA to market Tofacitinib tablets.

Infosys: The company has announced that it has strengthened its capabilities and presence in the turbomachinery and propulsion space with the opening of a new Infosys office in Baden, Switzerland.

Previous Article Markets may open flat with a positive bias amid positive global cues
Next Article Ambuja Cement forms Homing Pigeon pattern
Print
1291 Rate this article:
5.0
Please login or register to post comments.
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR